Johnson & Johnson (JNJ-N) Stock Predictions - Stockchase
WATCH LIST
406
Johnson & Johnson (JNJ-N)

ON STOCKCHASE SINCE Oct 2000

biotechnology/pharmaceutical

Johnson & Johnson

JNJ-N

153 watching          
Join the Discussion

Johnson & Johnson (JNJ-N) SAVE Jan, 23, 2019, 3:10 am

128.80 1.89 (1.45%)

About Johnson & Johnson (JNJ-N)

Johnson & Johnson is an American multinational medical devices, pharmaceutical and consumer packaged goods manufacturing company founded in 1886. More at Wikipedia

What the experts are saying about JNJ-N



  • All
  • Filtered
Signal Opinion Expert
COMMENT
Johnson & Johnson(JNJ-N) 

February 22, 2017

Their consumer line is very small on a relative basis, sub 10%. The company is fully diversified. A $325 billion market cap. You are paying a little bit lower than a broader market multiple. They have the ability to really commercialize a drug. Their recent acquisition of Actelion sounds like it is earnings accretive slightly this year and above market growth next year, with greater exposure into the lung market.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Their consumer line is very small on a relative basis, sub 10%. The company is fully diversified. A $325 billion market cap. You are paying a little bit lower than a broader market multiple. They have the ability to really commercialize a drug. Their recent acquisition of Actelion sounds like it is earnings accretive slightly this year and above market growth next year, with greater exposure into the lung market.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$119.520
Owned Owned
Yes

TOP PICK
Johnson & Johnson(JNJ-N) 

February 17, 2017

They have done well in the pharma side.  They just announced the acquisition of a Swiss based pharma company.  They grow organically also.  They have identified about 10 products they are going to launch in the next three years that have about $1 Billion each.  They trade at 16 times earnings and have increased their dividend for 54 consecutive years.  (Analysts’ target: $126.32).

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

They have done well in the pharma side.  They just announced the acquisition of a Swiss based pharma company.  They grow organically also.  They have identified about 10 products they are going to launch in the next three years that have about $1 Billion each.  They trade at 16 times earnings and have increased their dividend for 54 consecutive years.  (Analysts’ target: $126.32).

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Christine Poole

CEO & Mana, GlobeInvest Capital ...

Price Price
$118.860
Owned Owned
Yes

COMMENT
Johnson & Johnson(JNJ-N) 

January 27, 2017

Merck (MRK-N) or Johnson & Johnson (JNJ-N) for safety? For safety, he would attribute that more to this company. They have a great yield of about 2.8%, but keep in mind that as a Canadian investor, you do not get the dividend tax credit. This company has the pharma, medical devices and consumer products. The bet you are making is that they are going to be able to turn around the recent acquisition of the devices business, and that is a big bet, because they spent a lot of money. Expects some share price volatility over the next 6-18 months.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Merck (MRK-N) or Johnson & Johnson (JNJ-N) for safety? For safety, he would attribute that more to this company. They have a great yield of about 2.8%, but keep in mind that as a Canadian investor, you do not get the dividend tax credit. This company has the pharma, medical devices and consumer products. The bet you are making is that they are going to be able to turn around the recent acquisition of the devices business, and that is a big bet, because they spent a lot of money. Expects some share price volatility over the next 6-18 months.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Kash Pashootan

CEO & Chie, First Avenue Investm...

Price Price
$113.380
Owned Owned
No

DON'T BUY
Johnson & Johnson(JNJ-N) 

January 26, 2017

They made a major acquisition today.  The largest pharma in Europe, trying to pick up the drug.  JNJ is a well run company.  They were split evenly in the past between their businesses, but now the pharma is starting to dominate.  They are no longer to be compared with the consumer space.  But it is not a compelling opportunity to him based on fundamentals.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

They made a major acquisition today.  The largest pharma in Europe, trying to pick up the drug.  JNJ is a well run company.  They were split evenly in the past between their businesses, but now the pharma is starting to dominate.  They are no longer to be compared with the consumer space.  But it is not a compelling opportunity to him based on fundamentals.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Gordon Reid

President, GoodReid Investment ...

Price Price
$111.840
Owned Owned
Unknown

BUY
Johnson & Johnson(JNJ-N) 

January 25, 2017

A very well-managed company with a very solid footing. Valuation is reasonable and certainly belongs in a portfolio. It is more of a stabilizer rather than a driver of volatility. In the last couple of days, there has been some concern when guidance came in the little bit lower. He wouldn’t be surprised to see them make some acquisitions in 2017. 2.9% dividend yield.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

A very well-managed company with a very solid footing. Valuation is reasonable and certainly belongs in a portfolio. It is more of a stabilizer rather than a driver of volatility. In the last couple of days, there has been some concern when guidance came in the little bit lower. He wouldn’t be surprised to see them make some acquisitions in 2017. 2.9% dividend yield.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Dr. Richard Eva

Head of He, SSR...

Price Price
$112.800
Owned Owned
Unknown

HOLD
Johnson & Johnson(JNJ-N) 

January 24, 2017

The kind of stock you can put in the “buy, hold and forget about it” category. They have some well recognized brands. He doesn’t know what the Trump effect would be on this type of company. The company has a tremendous history of increasing shareholder wealth through increasing earnings per share, and increasing shareholder equity through their very attractive ROE.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

The kind of stock you can put in the “buy, hold and forget about it” category. They have some well recognized brands. He doesn’t know what the Trump effect would be on this type of company. The company has a tremendous history of increasing shareholder wealth through increasing earnings per share, and increasing shareholder equity through their very attractive ROE.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Jason Del Vicar

Portfolio , HollisWealth...

Price Price
$111.760
Owned Owned
Unknown

COMMENT
Johnson & Johnson(JNJ-N) 

January 19, 2017

A very well-run company. It has a huge number of products. It has a decent dividend and a good quality balance sheet. It has really been a growth by acquisition. Regarding the consumer products part of it, as Amazon (AMZN-Q) increasingly attracts shoppers, does this company capture part of that margin that is being taken away from retail and grocery stores? Can they allocate their advertising budget more efficiently and effectively? If these companies do start capturing part of that margin, ensuring that part of their profit with Amazon, then he thinks they are interesting. In the interim, he doesn’t think these are all that interesting.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

A very well-run company. It has a huge number of products. It has a decent dividend and a good quality balance sheet. It has really been a growth by acquisition. Regarding the consumer products part of it, as Amazon (AMZN-Q) increasingly attracts shoppers, does this company capture part of that margin that is being taken away from retail and grocery stores? Can they allocate their advertising budget more efficiently and effectively? If these companies do start capturing part of that margin, ensuring that part of their profit with Amazon, then he thinks they are interesting. In the interim, he doesn’t think these are all that interesting.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
John O'Connell,

Chairman a, Davis Rea...

Price Price
$114.200
Owned Owned
No

COMMENT
Johnson & Johnson(JNJ-N) 

January 17, 2017

A wonderful company. His only reservation is, if looking for healthcare, this company has a lot of over-the-counter of hairsprays, Band-Aids, etc. They have a wonderful dividend.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

A wonderful company. His only reservation is, if looking for healthcare, this company has a lot of over-the-counter of hairsprays, Band-Aids, etc. They have a wonderful dividend.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Dietze

Founder, P, Point View Wealth Ma...

Price Price
$114.870
Owned Owned
Unknown

BUY on WEAKNESS
Johnson & Johnson(JNJ-N) 

January 12, 2017

A great unique company and business model.  Pharma and personal care consumer businesses.  If you built a position at these levels you probably won’t regret it.  It will be akin to US GDP growth.  It will not be in the cross hairs of any pharma policy changes.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

A great unique company and business model.  Pharma and personal care consumer businesses.  If you built a position at these levels you probably won’t regret it.  It will be akin to US GDP growth.  It will not be in the cross hairs of any pharma policy changes.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Mohsin Bashir

VP Investm, Stone Asset Manageme...

Price Price
$114.620
Owned Owned
Unknown

PAST TOP PICK
Johnson & Johnson(JNJ-N) 

December 30, 2016

(A Top Pick Dec 31/15. Up 15.82%.) Sold his holdings as he felt it had run up a lot, and he had found other opportunities. You can’t go wrong owning this, but he just wanted to put money someplace else.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(A Top Pick Dec 31/15. Up 15.82%.) Sold his holdings as he felt it had run up a lot, and he had found other opportunities. You can’t go wrong owning this, but he just wanted to put money someplace else.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Harris, CF

Portfolio , Avenue Investment Ma...

Price Price
$115.210
Owned Owned
No

COMMENT
Johnson & Johnson(JNJ-N) 

December 23, 2016

One of the names you want to hold in the pharmaceutical healthcare area for the long term. The pharmaceutical healthcare field has had good earnings growth, and are expecting significant earnings growth next year, especially on the pharmacy side. These kinds of names were really hurt in 2016, because there was fear that if Clinton came in, they are going to start regulating prices along with additional regulations on the pharmaceutical industry. This trades at a premium to the group at about 20-21 times earnings. They have a great platform with a pipeline of about 10 medications that should be coming on market in the next 5 years. They are great at cost cutting. Also there is a potential acquisition they are looking at.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

One of the names you want to hold in the pharmaceutical healthcare area for the long term. The pharmaceutical healthcare field has had good earnings growth, and are expecting significant earnings growth next year, especially on the pharmacy side. These kinds of names were really hurt in 2016, because there was fear that if Clinton came in, they are going to start regulating prices along with additional regulations on the pharmaceutical industry. This trades at a premium to the group at about 20-21 times earnings. They have a great platform with a pipeline of about 10 medications that should be coming on market in the next 5 years. They are great at cost cutting. Also there is a potential acquisition they are looking at.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Lorne Zeiler

Portfolio , TriDelta Financial...

Price Price
$115.960
Owned Owned
Unknown

TOP PICK
Johnson & Johnson(JNJ-N) 

December 14, 2016

This is more broadly diversified than others in the pharmaceutical area. Pharmaceuticals is about 45% of their revenues. They have medical devices and diagnostics as well as their consumer products division. On the Pharma side, they have a very strong pipeline, and have identified 10 drugs that potentially have $1 billion revenue potential, that will be launching over the next 3 years. Attractively priced at about 16X forward earnings, below their market multiple. Dividend yield of 2.7%. Have consistently raised the dividend for 55 years.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

This is more broadly diversified than others in the pharmaceutical area. Pharmaceuticals is about 45% of their revenues. They have medical devices and diagnostics as well as their consumer products division. On the Pharma side, they have a very strong pipeline, and have identified 10 drugs that potentially have $1 billion revenue potential, that will be launching over the next 3 years. Attractively priced at about 16X forward earnings, below their market multiple. Dividend yield of 2.7%. Have consistently raised the dividend for 55 years.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Christine Poole

CEO & Mana, GlobeInvest Capital ...

Price Price
$114.990
Owned Owned
Yes

COMMENT
Johnson & Johnson(JNJ-N) 

December 13, 2016

With the pickup in financials, (which were really under owned by institutions, portfolio managers and investors), they looked at their holdings to see what they could sell, because there wasn’t a lot of new money coming into the market. A lot of the leading technology stocks and healthcare stocks sold off. In the last 2 weeks, we are starting to see net flows into equities, which could be the beginning of that great rotation that people talk about. Right now, healthcare is not one of the leading groups. There has been some tax loss selling, but feels we are getting towards the end of that. Some of these lagging groups are starting to bubble up. This is a great quality company.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

With the pickup in financials, (which were really under owned by institutions, portfolio managers and investors), they looked at their holdings to see what they could sell, because there wasn’t a lot of new money coming into the market. A lot of the leading technology stocks and healthcare stocks sold off. In the last 2 weeks, we are starting to see net flows into equities, which could be the beginning of that great rotation that people talk about. Right now, healthcare is not one of the leading groups. There has been some tax loss selling, but feels we are getting towards the end of that. Some of these lagging groups are starting to bubble up. This is a great quality company.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Burrows

President , Barometer Capital Ma...

Price Price
$115.890
Owned Owned
No

COMMENT
Johnson & Johnson(JNJ-N) 

December 7, 2016

There has recently been a massive rotation out of defensive areas, where you didn’t need to rely on GDP growth. This is a wonderful company. Trades between $100 and $120, and is probably going to trade in this range for a time. Large institutional companies will probably look at this as a source of cash, and looking elsewhere to deploy their capital. Dividend yield of 2.9%.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

There has recently been a massive rotation out of defensive areas, where you didn’t need to rely on GDP growth. This is a wonderful company. Trades between $100 and $120, and is probably going to trade in this range for a time. Large institutional companies will probably look at this as a source of cash, and looking elsewhere to deploy their capital. Dividend yield of 2.9%.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
James Thorne

Sr Portfol, Caldwell Investment ...

Price Price
$111.100
Owned Owned
Unknown

SELL
Johnson & Johnson(JNJ-N) 

December 1, 2016

This is expensive. It is at a very high valuation level on a Price to Book basis. His FMV was about $125 with a technical ceiling at about $130. Thinks the stock has pretty much had it, and he wouldn’t be invested in it.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

This is expensive. It is at a very high valuation level on a Price to Book basis. His FMV was about $125 with a technical ceiling at about $130. Thinks the stock has pretty much had it, and he wouldn’t be invested in it.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Ross Healy

Chairman, Strategic Analysis C...

Price Price
$111.380
Owned Owned
No

Showing 46 to 60 of 406 entries
Successfully Saved Company
Successfully Saved Company
9+
JOIN THE DISCUSSION
9 comments in the last 7 days